Topo-microtubule inhibitors Flashcards
which of the following is not a crosslinker?
a) cytarabine
b) cyclophosphamide
c) carboplatin
d) chlorambucil
cytarabine
to block hemorrhagic cystitis, Mesna is coadministered with which drug?
a) methotrexate
b) cyclophosphamide
c) cisplatin
d) mitomycin C
cyclophosphamide
Topoisomerase mechanisms
- DNA must be tightly coiled and packed around nucleosomes to fit in the nucleus
- transcription and translation induce ___
- topoisomerases reduce localized supercoiling and provide access to double stranded DNA by enzymes responsivle for replication, transcription, and repair
wire example in class
- supercoiling
cell cycle checkpoints and common chemotherapies
DNA damaging agents (non-cycle specific) (1)
DNA replication (1)
Sister chromatid separation (2)
- doxorubicin
- irinotecan
- etoposide
- bleomycin
topoisomerase I
- cut ___ strand of double stranded DNA
- relax the remaining strand
- reanneals
1
topoisomerase I inhibitors
- form a ternary drug-enzyme-DNA complex
- inhibition provides a ___ barrier to replication and transcription
- cells in ___ phase are most sensitive to Topo I induced cleavage
- most topo inhibitors share a polycyclic aromatic motif for ___
drug resistance
- P-glycoprotein overexpression
- multidrug resistant protein overexpression
- ___ S transferase over expression
- topoisomerase downregulation or muttion to prevent inhibitor binding
- physical
- S
- intercalation
- glutathione
topoisomerase I inhibitors Camptothecins
- semisynthetic analogs of the natural product camptothecin, a plant alkaloid obtained from Camptotheca acuminata
- all are potent inhibitors of Topo I - closed lactone ring essential for activity
- camptothecin has potent activity, but low solubility and severe/unpredictable toxicity - not used clinically
- ___ (Hycamtin) and ___ (Camtosar) are water soluble and are both used clinically
- topotecan
- irinotecan
Irinotecan (Camptosar)
SN-38 is metabolized by uridine diphosphate glucosyltransferase (UGT1A1)
- 10% of the pop has polymorphism predicting ___ expression of UGT1A1, leading to ___ toxicity
low
increased
topoisomerase I inhibitors primarily halt cells in which phase of the cell cycle?
a) G0/G1
b) S
c) G2
d) M
S
topoisomerase II
relieves torsional strain AND untangles DNA by catalyzing ___ stranded DNA breaks
double
many compounds inhibit Top2
only ones that produce ___ stranded DNA breaks are cancer therapies
double
topoisomerase II inhibitors - doxorubicin
- natural products containing a planar ___ ring linked to an amino sugar
- presence of ___ group at R4 confers different clinical properties
polycyclic
OH
multiple mechanisms of toxicity - Topo II
multiple mechanisms of toxicity
- intercalator
- free radical cause DNA damage
- inhibition of Topo II presumed to be most important therapeutically
free radical damage causes __ since heart tissue has low levels of enzymes that neutralize ___ ___
although activity is greater G2/M they are ___ dependent
- cardiotoxicity, free radicals
- non-cycle
Doxorubicin (Adriamycin)
increased therapeutic index over the original anthracycline, daunorubicin
most widely used (best understood anthracycline)
Toxicity
- ___ - damage to cardiac muscle dependent on cumulative dose
- severe local tissue damage if ___ (leakage out of vessels)
red color adn bad side effects = “red devil”
- cardiotoxicity
- extravasated
Topo II inhibitors - anthracyclines
also in this class:
daunorubicin
- OG anthracycline natural product
- cardiotoxicity
epirubicin
- cardiotoxicity ___ severe than with doxorubicin - ___ elimination
idarubicin
- increased ___ solubility and cellular uptake
liposomal doxorubicin
- PEG-based formulation for __ release
- less, faster
- fat
- extended